Project description DEENESFRITPL A novel device for objective pupillary assessment A pupillary exam estimates the size and shape of the pupil at rest alongside its responses following eye illumination. This exam is based on the neurological control of the pupil and is employed to diagnose a number of conditions including traumatic brain injury following head trauma. The EU-funded PUPILOSCOPE project has developed a breakthrough technology that allows the quantitative real-time monitoring of pupillary responses. The idea behind the novel device is to overcome the human error-prone nature of conventional pupillary exams. Importantly, it does not require any expert training and offers a powerful tool in emergency care medicine especially for patients with head trauma. Show the project objective Hide the project objective Objective An estimated 42 million people Worldwide suffer a Head Injury (2.5 million in the EU) that can lead to Mild or Traumatic Brain Injury (TBI). It is a major cause of death and disability, especially in young people, impacting victims and relatives, with significant costs to society, estimated at €33 Billion per annum in Europe alone. Pre-Hospital and Emergency Care Neuro-Monitoring, including pupillary assessment, is critical in the processes of triage, management and medicating patients to prevent secondary injury to the brain. However, the current method of shining a light into a patient's eyes, in order to estimate pupillary response, is subjective and prone to human error.The solution is Pupiloscope®, enabling Accurate, Real-time, Quantitative Pupillary Monitoring and Assessment for patients with potentially life threatening head injuries. Pupiloscope is a breakthrough technology that will positively impact clinical pathways as well as patient outcomes. It is quick, simple, and easy to use by Doctors, Nurses and Paramedics of all skill levels. Through collaboration with industry experts, key opinion leaders, engineers and Emergency Care based clinicians, who identified the unmet clinical need, ViVO has successfully developed a functional prototype to TRL 6. As a direct result of this project, Pupiloscope forecasts sales of €20 Million within 5 years of product launch, improving patient outcomes and reducing both the societal and costs of care in the EU and Globally by an estimated €2 Billion per annum.This project will seek to develop Pupiloscope into a clinically proven, manufacturing ready and CE approved medical device; incorporating technology finalisation, regulatory approval, health economics, clinical testing and validation, therefore enabling product launch and sales to the EU and Global Emergency Care healthcare markets. Fields of science natural sciencescomputer and information sciencessoftwaresocial scienceseconomics and businesseconomicsproduction economicsproductivityengineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensorssocial scienceseconomics and businesseconomicshealth economics Keywords Pupillary Assessment Eye Neuromonitoring Patient Pupil Neurotrauma Head Injury Patient Care Monitoring Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-2 Funding Scheme SME-2 - SME instrument phase 2 Coordinator VIVO SMART MEDICAL DEVICES LTD Net EU contribution € 875 637,88 Address 6 EDISON VILLAGE NOTTINGHAM SCIENCE TECHNOLOGY PARK NG7 2RF Nottingham United Kingdom See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region East Midlands (England) Derbyshire and Nottinghamshire Nottingham Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 1 250 911,25
